{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:30:41Z","timestamp":1782761441321,"version":"3.54.5"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Barrett's esophagus, a columnar metaplasia of the lower esophagus epithelium related to gastroesophageal reflux disease, is the strongest known risk factor for the development of esophageal adenocarcinoma (EAC). Understanding the signal transduction events involved in esophageal epithelium carcinogenesis may provide insights into the origins of EAC and may suggest new therapies. To elucidate the molecular pathways of bile acid\u2013induced tumorigenesis, the newly identified inflammation-associated signaling pathway involving I\u03baB kinases \u03b2 (IKK\u03b2), tuberous sclerosis complex 1 (TSC1), and mammalian target of rapamycin (mTOR) downstream effector S6 kinase (S6K1) was confirmed to be activated in immortalized Barrett's CPC-A and CPC-C cells and esophageal cancer SEG-1 and BE3 cells. Phosphorylation of TSC1 and S6K1 was induced in response to bile acid stimulation. Treatment of these cells with the mTOR inhibitor rapamycin or the IKK\u03b2 inhibitor Bay 11-7082 suppressed bile acid\u2013induced cell proliferation and anchorage-independent growth. We next used an orthotopic rat model to evaluate the role of bile acid in the progression of Barrett's esophagus to EAC. Of interest, we found high expression of phosphorylated IKK\u03b2 (pIKK\u03b2) and phosphorylated S6K1 (pS6K1) in tumor tissues and the Barrett's epithelium compared with normal epithelium. Furthermore, immunostaining of clinical EAC tissue specimens revealed that pIKK\u03b2 expression was strongly correlated with pS6K1 level. Together, these results show that bile acid can deregulate TSC1\/mTOR through IKK\u03b2 signaling, which may play a critical role in EAC progression. In addition, Bay 11-7082 and rapamycin may potentially be chemopreventive drugs against Barrett's esophagus\u2013associated EAC. [Cancer Res 2008;68(8):2632\u201340]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5460","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T14:14:04Z","timestamp":1208268844000},"page":"2632-2640","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1\/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma"],"prefix":"10.1158","volume":"68","author":[{"given":"Chia-Jui","family":"Yen","sequence":"first","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"},{"name":"9Institute of Clinical Medicine, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie G.","family":"Izzo","sequence":"additional","affiliation":[{"name":"2Experimental Therapeutics,"},{"name":"4Gastrointestinal Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung-Fang","family":"Lee","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"},{"name":"7Graduate School of Biomedical Sciences, University of Texas, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushovan","family":"Guha","sequence":"additional","affiliation":[{"name":"3Gastrointestinal Medicine and Nutrition,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkun","family":"Wei","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Teh","family":"Wu","sequence":"additional","affiliation":[{"name":"5Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Te","family":"Chen","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"},{"name":"7Graduate School of Biomedical Sciences, University of Texas, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Ping","family":"Kuo","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"},{"name":"7Graduate School of Biomedical Sciences, University of Texas, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Mao","family":"Hsu","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"},{"name":"7Graduate School of Biomedical Sciences, University of Texas, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Lung","family":"Sun","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Kai","family":"Chou","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"},{"name":"7Graduate School of Biomedical Sciences, University of Texas, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navtej S.","family":"Buttar","sequence":"additional","affiliation":[{"name":"8Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.","family":"Wang","sequence":"additional","affiliation":[{"name":"8Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[{"name":"6Molecular Pathology, University of Texas M. D. Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer","family":"Ajani","sequence":"additional","affiliation":[{"name":"4Gastrointestinal Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[{"name":"1Molecular and Cellular Oncology, Departments of"},{"name":"7Graduate School of Biomedical Sciences, University of Texas, Houston, Texas;"},{"name":"10Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,4,15]]},"reference":[{"key":"2022061700420690000_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin\u20082006; 56: 106\u201330.","DOI":"10.3322\/canjclin.56.2.106"},{"key":"2022061700420690000_B2","doi-asserted-by":"crossref","unstructured":"Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst\u20082005; 97: 142\u20136.","DOI":"10.1093\/jnci\/dji024"},{"key":"2022061700420690000_B3","doi-asserted-by":"crossref","unstructured":"El-Serag HB, Mason AC, Petersen N, Key CR. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut\u20082002; 50: 368\u201372.","DOI":"10.1136\/gut.50.3.368"},{"key":"2022061700420690000_B4","doi-asserted-by":"crossref","unstructured":"Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken \u2018on-demand.\u2019 Aliment Pharmacol Ther\u20082007; 26: 195\u2013204.","DOI":"10.1111\/j.1365-2036.2007.03381.x"},{"key":"2022061700420690000_B5","doi-asserted-by":"crossref","unstructured":"Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med\u20082002; 346: 836\u201342.","DOI":"10.1056\/NEJMcp012118"},{"key":"2022061700420690000_B6","doi-asserted-by":"crossref","unstructured":"Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology\u20081996; 110: 614\u201321.","DOI":"10.1053\/gast.1996.v110.agast960614"},{"key":"2022061700420690000_B7","doi-asserted-by":"crossref","unstructured":"Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut\u20082006; 55: 442.","DOI":"10.1136\/gut.2005.083600"},{"key":"2022061700420690000_B8","doi-asserted-by":"crossref","unstructured":"Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut\u20082004; 53: 1070\u20134.","DOI":"10.1136\/gut.2003.028076"},{"key":"2022061700420690000_B9","doi-asserted-by":"crossref","unstructured":"Dhillon PK, Farrow DC, Vaughan TL, et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer\u20082001; 93: 148\u201352.","DOI":"10.1002\/ijc.1294"},{"key":"2022061700420690000_B10","doi-asserted-by":"crossref","unstructured":"Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology\u20082005; 129: 1825\u201331.","DOI":"10.1053\/j.gastro.2005.08.053"},{"key":"2022061700420690000_B11","doi-asserted-by":"crossref","unstructured":"Dvorak K, Payne CM, Chavarria M, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut\u20082007; 56: 763\u201371.","DOI":"10.1136\/gut.2006.103697"},{"key":"2022061700420690000_B12","doi-asserted-by":"crossref","unstructured":"Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut\u20081999; 44: 598\u2013602.","DOI":"10.1136\/gut.44.5.598"},{"key":"2022061700420690000_B13","doi-asserted-by":"crossref","unstructured":"Zhang F, Altorki NK, Wu YC, Soslow RA, Subbaramaiah K, Dannenberg AJ. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology\u20082001; 121: 1391\u20139.","DOI":"10.1053\/gast.2001.29781"},{"key":"2022061700420690000_B14","doi-asserted-by":"crossref","unstructured":"Atherfold PA, Jankowski JA. Molecular biology of Barrett's cancer. Best Pract Res Clin Gastroenterol\u20082006; 20: 813\u201327.","DOI":"10.1016\/j.bpg.2006.04.003"},{"key":"2022061700420690000_B15","doi-asserted-by":"crossref","unstructured":"Jenkins GJ, Harries K, Doak SH, et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-\u03baB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis\u20082004; 25: 317\u201323.","DOI":"10.1093\/carcin\/bgh032"},{"key":"2022061700420690000_B16","doi-asserted-by":"crossref","unstructured":"Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology\u20082002; 122: 1800\u20137.","DOI":"10.1053\/gast.2002.33580"},{"key":"2022061700420690000_B17","doi-asserted-by":"crossref","unstructured":"Cheong E, Ivory K, Doleman J, Parker ML, Rhodes M, Johnson IT. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis\u20082004; 25: 1945\u201352.","DOI":"10.1093\/carcin\/bgh184"},{"key":"2022061700420690000_B18","doi-asserted-by":"crossref","unstructured":"Tselepis C, Morris CD, Wakelin D, et al. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut\u20082003; 52: 174\u201380.","DOI":"10.1136\/gut.52.2.174"},{"key":"2022061700420690000_B19","doi-asserted-by":"crossref","unstructured":"Smith CJ, Perfetti TA, King JA. Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. Inhal Toxicol\u20082006; 18: 667\u201377.","DOI":"10.1080\/08958370600742821"},{"key":"2022061700420690000_B20","doi-asserted-by":"crossref","unstructured":"Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor \u03b2 signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology\u20082007; 46: 48\u201357.","DOI":"10.1002\/hep.21672"},{"key":"2022061700420690000_B21","doi-asserted-by":"crossref","unstructured":"Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol\u20081987; 87: 301\u201312.","DOI":"10.1093\/ajcp\/87.3.301"},{"key":"2022061700420690000_B22","doi-asserted-by":"crossref","unstructured":"Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol\u20082001; 32: 379\u201388.","DOI":"10.1053\/hupa.2001.23511"},{"key":"2022061700420690000_B23","doi-asserted-by":"crossref","unstructured":"Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol\u20081999; 154: 965\u201373.","DOI":"10.1016\/S0002-9440(10)65346-1"},{"key":"2022061700420690000_B24","doi-asserted-by":"crossref","unstructured":"Jankowski J, Sharma P. Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions. Aliment Pharmacol Ther\u20082004; 19 Suppl 1: 54\u20139.","DOI":"10.1111\/j.0953-0673.2004.01839.x"},{"key":"2022061700420690000_B25","doi-asserted-by":"crossref","unstructured":"Tselepis C, Perry I, Dawson C, et al. Tumour necrosis factor-\u03b1 in Barrett's oesophagus: a potential novel mechanism of action. Oncogene\u20082002; 21: 6071\u201381.","DOI":"10.1038\/sj.onc.1205731"},{"key":"2022061700420690000_B26","doi-asserted-by":"crossref","unstructured":"Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut\u20082002; 51: 316\u201322.","DOI":"10.1136\/gut.51.3.316"},{"key":"2022061700420690000_B27","doi-asserted-by":"crossref","unstructured":"Gough MD, Ackroyd R, Majeed AW, Bird NC. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important? Am J Gastroenterol\u20082005; 100: 1012\u20138.","DOI":"10.1111\/j.1572-0241.2005.40904.x"},{"key":"2022061700420690000_B28","doi-asserted-by":"crossref","unstructured":"Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[\u03ba]B activity. Annu Rev Immunol\u20082000; 18: 621\u201363.","DOI":"10.1146\/annurev.immunol.18.1.621"},{"key":"2022061700420690000_B29","doi-asserted-by":"crossref","unstructured":"Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-\u03b1 are resistant to skin carcinogenesis. Nat Med\u20081999; 5: 828\u201331.","DOI":"10.1038\/10552"},{"key":"2022061700420690000_B30","doi-asserted-by":"crossref","unstructured":"Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor \u03baB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol\u20082006; 24: 748\u201354.","DOI":"10.1200\/JCO.2005.03.8810"},{"key":"2022061700420690000_B31","doi-asserted-by":"crossref","unstructured":"Kwiatkowski DJ, Zhang H, Bandura JL, et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet\u20082002; 11: 525\u201334.","DOI":"10.1093\/hmg\/11.5.525"},{"key":"2022061700420690000_B32","doi-asserted-by":"crossref","unstructured":"Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A\u20082002; 99: 13571\u20136.","DOI":"10.1073\/pnas.202476899"},{"key":"2022061700420690000_B33","doi-asserted-by":"crossref","unstructured":"Segrelles C, Ruiz S, Santos M, Martinez-Palacio J, Lara MF, Paramio JM. Akt mediates an angiogenic switch in transformed keratinocytes. Carcinogenesis\u20082004; 25: 1137\u201347.","DOI":"10.1093\/carcin\/bgh132"},{"key":"2022061700420690000_B34","doi-asserted-by":"crossref","unstructured":"Lee DF, Kuo HP, Chen CT, et al. IKK\u03b2 suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell\u20082007; 130: 440\u201355.","DOI":"10.1016\/j.cell.2007.05.058"},{"key":"2022061700420690000_B35","doi-asserted-by":"crossref","unstructured":"Lee DF, Hung MC. All Roads Lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle\u20082007; 6: 3011\u20134.","DOI":"10.4161\/cc.6.24.5085"},{"key":"2022061700420690000_B36","doi-asserted-by":"crossref","unstructured":"Palanca-Wessels MC, Klingelhutz A, Reid BJ, et al. Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis\u20082003; 24: 1183\u201390.","DOI":"10.1093\/carcin\/bgg076"},{"key":"2022061700420690000_B37","doi-asserted-by":"crossref","unstructured":"Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2\/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene\u20081997; 15: 953\u201360.","DOI":"10.1038\/sj.onc.1201250"},{"key":"2022061700420690000_B38","unstructured":"Yan DH, Chang LS, Hung MC. Repressed expression of the HER-2\/c-erbB-2 proto-oncogene by the adenovirus E1a gene products. Oncogene\u20081991; 6: 343\u20135."},{"key":"2022061700420690000_B39","doi-asserted-by":"crossref","unstructured":"Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology\u20082002; 122: 1101\u201312.","DOI":"10.1053\/gast.2002.32371"},{"key":"2022061700420690000_B40","doi-asserted-by":"crossref","unstructured":"Chang JY, Xia W, Shao R, et al. The tumor suppression activity of E1A in HER-2\/neu-overexpressing breast cancer. Oncogene\u20081997; 14: 561\u20138.","DOI":"10.1038\/sj.onc.1200861"},{"key":"2022061700420690000_B41","doi-asserted-by":"crossref","unstructured":"Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays\u20082000; 22: 673\u201380.","DOI":"10.1002\/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A"},{"key":"2022061700420690000_B42","doi-asserted-by":"crossref","unstructured":"Maley CC, Rustgi AK. Barrett's esophagus and its progression to adenocarcinoma. J Natl Compr Canc Netw\u20082006; 4: 367\u201374.","DOI":"10.6004\/jnccn.2006.0031"},{"key":"2022061700420690000_B43","doi-asserted-by":"crossref","unstructured":"Buttar NS, Wang KK. Mechanisms of disease: carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol\u20082004; 1: 106\u201312.","DOI":"10.1038\/ncpgasthep0057"},{"key":"2022061700420690000_B44","doi-asserted-by":"crossref","unstructured":"Nishijima K, Miwa K, Miyashita T, et al. Impact of the biliary diversion procedure on carcinogenesis in Barrett's esophagus surgically induced by duodenoesophageal reflux in rats. Ann Surg\u20082004; 240: 57\u201367.","DOI":"10.1097\/01.sla.0000130850.31178.8c"},{"key":"2022061700420690000_B45","doi-asserted-by":"crossref","unstructured":"Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol\u20082007; 63: 172\u201382.","DOI":"10.1016\/j.critrevonc.2007.04.002"},{"key":"2022061700420690000_B46","doi-asserted-by":"crossref","unstructured":"Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol\u20082005; 23: 5314\u201322.","DOI":"10.1200\/JCO.2005.66.130"},{"key":"2022061700420690000_B47","doi-asserted-by":"crossref","unstructured":"Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin\u20082007; 57: 112\u201325.","DOI":"10.3322\/canjclin.57.2.112"},{"key":"2022061700420690000_B48","doi-asserted-by":"crossref","unstructured":"Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev\u20082007; 33: 78\u201384.","DOI":"10.1016\/j.ctrv.2006.10.004"},{"key":"2022061700420690000_B49","doi-asserted-by":"crossref","unstructured":"Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer\u20082005; 104: 1045\u20138.","DOI":"10.1002\/cncr.21265"},{"key":"2022061700420690000_B50","doi-asserted-by":"crossref","unstructured":"Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced I\u03baB\u03b1 phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem\u20081997; 272: 21096\u2013103.","DOI":"10.1074\/jbc.272.34.21096"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/8\/2632\/2601956\/2632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/8\/2632\/2601956\/2632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:33:00Z","timestamp":1655433180000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/8\/2632\/543134\/Bile-Acid-Exposure-Up-regulates-Tuberous-Sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,15]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2008,4,15]]},"published-print":{"date-parts":[[2008,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5460","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1115376.571398","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,15]]}}}